Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

Sheldon L. Bolds, Shruthi M.K. Hassan, Catherine R. Caprara, Stephanie Debragga, Kathryn S. Simon, Prachi Karkhanis, Arpita Gandhi, Anand P. Jillella, Vamsi K. Kota

Research output: Contribution to journalArticle

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.

Original languageEnglish (US)
Article number7896
Pages (from-to)28-29
Number of pages2
JournalHematology Reports
Volume11
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Clinical Protocols
Formularies
Directories
Medicare
Acute Myeloid Leukemia
Registries
Epidemiology
Survival Rate
Clinical Trials
Guidelines
Mortality
Population
Therapeutics

Keywords

  • Acute promyelocytic leukemia
  • Early deaths
  • Supportive care

ASJC Scopus subject areas

  • Hematology

Cite this

Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA. / Bolds, Sheldon L.; Hassan, Shruthi M.K.; Caprara, Catherine R.; Debragga, Stephanie; Simon, Kathryn S.; Karkhanis, Prachi; Gandhi, Arpita; Jillella, Anand P.; Kota, Vamsi K.

In: Hematology Reports, Vol. 11, No. 2, 7896, 01.01.2019, p. 28-29.

Research output: Contribution to journalArticle

Bolds, Sheldon L. ; Hassan, Shruthi M.K. ; Caprara, Catherine R. ; Debragga, Stephanie ; Simon, Kathryn S. ; Karkhanis, Prachi ; Gandhi, Arpita ; Jillella, Anand P. ; Kota, Vamsi K. / Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA. In: Hematology Reports. 2019 ; Vol. 11, No. 2. pp. 28-29.
@article{c453f41ccfcc4c1eb9a38d7fe7426afe,
title = "Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA",
abstract = "Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.",
keywords = "Acute promyelocytic leukemia, Early deaths, Supportive care",
author = "Bolds, {Sheldon L.} and Hassan, {Shruthi M.K.} and Caprara, {Catherine R.} and Stephanie Debragga and Simon, {Kathryn S.} and Prachi Karkhanis and Arpita Gandhi and Jillella, {Anand P.} and Kota, {Vamsi K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.4081/hr.2019.7896",
language = "English (US)",
volume = "11",
pages = "28--29",
journal = "Hematology Reports",
issn = "2038-8322",
publisher = "PagePress",
number = "2",

}

TY - JOUR

T1 - Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA

AU - Bolds, Sheldon L.

AU - Hassan, Shruthi M.K.

AU - Caprara, Catherine R.

AU - Debragga, Stephanie

AU - Simon, Kathryn S.

AU - Karkhanis, Prachi

AU - Gandhi, Arpita

AU - Jillella, Anand P.

AU - Kota, Vamsi K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.

AB - Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.

KW - Acute promyelocytic leukemia

KW - Early deaths

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=85069669978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069669978&partnerID=8YFLogxK

U2 - 10.4081/hr.2019.7896

DO - 10.4081/hr.2019.7896

M3 - Article

AN - SCOPUS:85069669978

VL - 11

SP - 28

EP - 29

JO - Hematology Reports

JF - Hematology Reports

SN - 2038-8322

IS - 2

M1 - 7896

ER -